Neurocrine Biosciences, Inc. which can be found using ticker (NBIX) now have 24 analysts in total covering the stock. The consensus rating is pointing to ‘buy’. The target price High/Low ranges between 150 and 91 calculating the average target price we see $124.67. Now with the previous closing price of $93.50 this indicates there is a potential upside of 33.3%. The 50 day MA is $99.15 while the 200 day moving average is $107.69. The market cap for the company is 9.14B. The current stock price for Targa Resources Corp. is currently 93.64 USD
The potential market cap would be $12,182,864,659 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 148.63, revenue per share of 16.61 and a 7.65% return on assets.
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is focused on discovering and developing pharmaceuticals for the treatment of neurological, endocrine and psychiatric-based diseases and disorders. Its portfolio includes treatments for tardive dyskinesia, Parkinson’s disease, endometriosis and uterine fibroids. Its product pipeline includes INGREZZA (valbenazine), which provides a once-daily dosing treatment option for tardive dyskinesia and has three dosing options (40 milligrams (mg), 60 mg and 80 mg capsules); ONGENTYS (opicapone) is an adjunctive therapy to levodopa/carbidopa in patients with Parkinson’s disease; ORILISSA (elagolix) is used for the management of moderate to severe endometriosis pain in women. Its pipeline also includes DYSVAL (valbenazine), ORIAHNN (elagolix, estradiol, and norethindrone acetate and elagolix capsules), ALKINDI/ALKINDI SPRINKLE (hydrocortisone), and EFMODY (hydrocortisone modified-release hard capsules).
